This announcement is a separate document:
信達生物：自願公告 - 國家藥品監督管理局受理IBI-351（KRAS G12C抑制劑）的新藥上市申請並納入優先審評
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO THE NEW DRUG APPLICATION FOR IBI-351 (KRAS G12C INHIBITOR)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.